Xiaohui Ge, Yu Yang, Wenyan Wang, Lei Tian, Ge Zhang, Z. Tian, X. Xue
{"title":"Pediatric H3K27M‑mutant diffuse midline glioma with vertebral metastasis: A case report and literature review","authors":"Xiaohui Ge, Yu Yang, Wenyan Wang, Lei Tian, Ge Zhang, Z. Tian, X. Xue","doi":"10.3892/ol.2023.14181","DOIUrl":"https://doi.org/10.3892/ol.2023.14181","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"51 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138591717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Likun Mu, Mingxin Wang, Lifeng Cheng, Guangxu Chu, Zuyao Song
{"title":"Atypical meningioma with destruction of cervical vertebrae inside the spinal canal: A case report and literature review","authors":"Likun Mu, Mingxin Wang, Lifeng Cheng, Guangxu Chu, Zuyao Song","doi":"10.3892/ol.2023.14178","DOIUrl":"https://doi.org/10.3892/ol.2023.14178","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"79 10","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138596032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan Yang, Jie Du, Yun-Fei Huang, Wei He, Li Liu, Dan Li, Rui Chen
{"title":"Identification of TFR2 as a novel ferroptosis‑related gene that serves an important role in prognosis and progression of triple‑negative breast cancer","authors":"Yan Yang, Jie Du, Yun-Fei Huang, Wei He, Li Liu, Dan Li, Rui Chen","doi":"10.3892/ol.2023.14176","DOIUrl":"https://doi.org/10.3892/ol.2023.14176","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"39 10","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138600807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Beatriz Santana, J. Soriano, Octavio Arencibia, S. Petousis, C. Margioula-Siarkou, Daniel González, Maria Laseca, Andrés Rave, Alicia Martínez
{"title":"Impact of weight loss after treatment on survival outcomes of overweight and obese patients with early‑stage endometrial cancer","authors":"Beatriz Santana, J. Soriano, Octavio Arencibia, S. Petousis, C. Margioula-Siarkou, Daniel González, Maria Laseca, Andrés Rave, Alicia Martínez","doi":"10.3892/ol.2023.14177","DOIUrl":"https://doi.org/10.3892/ol.2023.14177","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"34 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138600639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shengsheng Liang, Bowen Dang, Shaohua Chen, Hua Mi
. The cathepsin S (CTSS) gene encodes a lysine cysteine protease and serves an important role in the development of autoimmune diseases, inflammation and nervous system diseases. Furthermore, CTSS is implicated in tumor invasion and metastasis by the induction of tumor angiogenesis and the degradation of the tumor extracel‑ lular matrix. Nevertheless, the precise impact of CTSS on predicting pan‑cancer prognosis and its influence on the tumor microenvironment and immune infiltration in human cancers remains unknown. This present study employed a comprehensive array of bioinformatic methods to evaluate the expression of CTSS and its associations with prognosis, clinicopathological characteristics, tumor microenviron‑ ment, tumor immune infiltration, tumor mutational burden and microsatellite instability across numerous cancer types. The current study demonstrated abnormal expression and distinct genomic alteration profiles of CTSS in many of the cancers tested. Furthermore, CTSS expression exhibited close associations with the prognosis of numerous cancers. High CTSS expression was significantly associated with better overall survival and disease‑specific survival in bladder urothelial carcinoma (BLCA) and skin cutaneous melanoma (SKCM) but worse outcomes in brain lower grade glioma (LGG) and uveal melanoma (UVM). Moreover, CTSS demonstrated significant correlations with tumor mutational burden and microsatellite instability in 8 and 12 cancer types respectively, as well as different responses in immu‑ notherapy sub‑cohorts, especially in melanoma and bladder cancers. CTSS expression showed a positive correlation with stromal and immune cell scores in the four aforementioned cancers. Moreover, CTSS expression was correlated with the number of infiltrating CD8 + T cells, CD4 + T cells and macrophages. Conversely, CTSS was negatively associated with resting Mast cells, resting NK cells and resting memory CD4 + T cell infiltration in BLCA, SKCM and kidney renal clear cell carcinoma (KIRC). Furthermore, CTSS expression was correlated with immune‑related gene expression, notably PDCD1,
{"title":"Prognostic value and immunological role of cathepsin S gene in pan‑cancer","authors":"Shengsheng Liang, Bowen Dang, Shaohua Chen, Hua Mi","doi":"10.3892/ol.2023.14175","DOIUrl":"https://doi.org/10.3892/ol.2023.14175","url":null,"abstract":". The cathepsin S (CTSS) gene encodes a lysine cysteine protease and serves an important role in the development of autoimmune diseases, inflammation and nervous system diseases. Furthermore, CTSS is implicated in tumor invasion and metastasis by the induction of tumor angiogenesis and the degradation of the tumor extracel‑ lular matrix. Nevertheless, the precise impact of CTSS on predicting pan‑cancer prognosis and its influence on the tumor microenvironment and immune infiltration in human cancers remains unknown. This present study employed a comprehensive array of bioinformatic methods to evaluate the expression of CTSS and its associations with prognosis, clinicopathological characteristics, tumor microenviron‑ ment, tumor immune infiltration, tumor mutational burden and microsatellite instability across numerous cancer types. The current study demonstrated abnormal expression and distinct genomic alteration profiles of CTSS in many of the cancers tested. Furthermore, CTSS expression exhibited close associations with the prognosis of numerous cancers. High CTSS expression was significantly associated with better overall survival and disease‑specific survival in bladder urothelial carcinoma (BLCA) and skin cutaneous melanoma (SKCM) but worse outcomes in brain lower grade glioma (LGG) and uveal melanoma (UVM). Moreover, CTSS demonstrated significant correlations with tumor mutational burden and microsatellite instability in 8 and 12 cancer types respectively, as well as different responses in immu‑ notherapy sub‑cohorts, especially in melanoma and bladder cancers. CTSS expression showed a positive correlation with stromal and immune cell scores in the four aforementioned cancers. Moreover, CTSS expression was correlated with the number of infiltrating CD8 + T cells, CD4 + T cells and macrophages. Conversely, CTSS was negatively associated with resting Mast cells, resting NK cells and resting memory CD4 + T cell infiltration in BLCA, SKCM and kidney renal clear cell carcinoma (KIRC). Furthermore, CTSS expression was correlated with immune‑related gene expression, notably PDCD1,","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"49 21","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138602350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
. Primary cardiac lymphomas display a low frequency, sudden onset, swift progression of illness and elevated mortality rates. The current study presents a unique instance of primary cardiac diffuse large B‑cell lymphoma and examines its clinical manifestations, pathological charac‑ teristics and differential diagnosis. A 64‑year‑old male patient sought medical attention due to cardiac debility and exertional dyspnea persisting for >10 days. Chest enhanced computed tomography revealed a moderately enhancing irregular mass in the ventricular area, exhibiting limited demarcation from the pericardium and left atrium, accompanied by irregular thickening of the interventricular septum. The postopera‑ tive specimen showed the presence of yellow fish‑like tumor tissue. Immunohistochemical analysis revealed the pres‑ ence of lymphocytes positive for CD20, BCL‑2, BCL‑6, c‑Myc‑binding protein, mutated melanoma‑associated antigen 1 and CD79a, along with a high Ki‑67 proliferation index of 80%. Conversely, CD10, CD30, CD3, pan cytokeratin, cyclin D1, desmin and vimentin marker results were found to be nega‑ tive. Additionally, in situ hybridization demonstrated a lack of Epstein‑Barr virus‑encoded small RNA expression. The present case report emphasizes the significance of conducting a thorough analysis of the clinical manifestations of diffuse large B‑cell lymphoma to assist clinicians in establishing a diagnosis and determining an effective treatment approach, thereby enhancing the patient's prognosis.
{"title":"A rare presentation of primary cardiac diffuse large B‑cell lymphoma: A case report","authors":"Hongyan Jiang, Haijun Liu, Linwei Zhao, Ling Yang, Yunfei Zhao","doi":"10.3892/ol.2023.14174","DOIUrl":"https://doi.org/10.3892/ol.2023.14174","url":null,"abstract":". Primary cardiac lymphomas display a low frequency, sudden onset, swift progression of illness and elevated mortality rates. The current study presents a unique instance of primary cardiac diffuse large B‑cell lymphoma and examines its clinical manifestations, pathological charac‑ teristics and differential diagnosis. A 64‑year‑old male patient sought medical attention due to cardiac debility and exertional dyspnea persisting for >10 days. Chest enhanced computed tomography revealed a moderately enhancing irregular mass in the ventricular area, exhibiting limited demarcation from the pericardium and left atrium, accompanied by irregular thickening of the interventricular septum. The postopera‑ tive specimen showed the presence of yellow fish‑like tumor tissue. Immunohistochemical analysis revealed the pres‑ ence of lymphocytes positive for CD20, BCL‑2, BCL‑6, c‑Myc‑binding protein, mutated melanoma‑associated antigen 1 and CD79a, along with a high Ki‑67 proliferation index of 80%. Conversely, CD10, CD30, CD3, pan cytokeratin, cyclin D1, desmin and vimentin marker results were found to be nega‑ tive. Additionally, in situ hybridization demonstrated a lack of Epstein‑Barr virus‑encoded small RNA expression. The present case report emphasizes the significance of conducting a thorough analysis of the clinical manifestations of diffuse large B‑cell lymphoma to assist clinicians in establishing a diagnosis and determining an effective treatment approach, thereby enhancing the patient's prognosis.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"13 5","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138603755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meltem Kaba, Ç. Karadağ, Serkan Odabaşi, Dildar Genç
. Rhabdomyosarcoma (RMS) is the most common soft‑tissue sarcoma in children. The present study reports the case of a 2‑year‑old female who presented with abdominal pain and a palpable abdominal mass. Radiological investiga‑ tions failed to reveal the tissue origin of the mass and a tru‑cut biopsy confirmed the diagnosis of embryonal RMS. Surgical excision was performed after neo‑adjuvant chemotherapy. The pelvic end of the mass was observed to continue with the left medial umbilical ligament. The patient's postoperative course was uneventful, and follow‑up imaging showed no evidence of recurrence. Τhe present case report is the first non‑syndromic case with left umbilical medial ligament‑originated
{"title":"Non‑syndromic first case of pediatric rhabdomyosarcoma originating from the umbilical left medial ligament: A case report","authors":"Meltem Kaba, Ç. Karadağ, Serkan Odabaşi, Dildar Genç","doi":"10.3892/ol.2023.14171","DOIUrl":"https://doi.org/10.3892/ol.2023.14171","url":null,"abstract":". Rhabdomyosarcoma (RMS) is the most common soft‑tissue sarcoma in children. The present study reports the case of a 2‑year‑old female who presented with abdominal pain and a palpable abdominal mass. Radiological investiga‑ tions failed to reveal the tissue origin of the mass and a tru‑cut biopsy confirmed the diagnosis of embryonal RMS. Surgical excision was performed after neo‑adjuvant chemotherapy. The pelvic end of the mass was observed to continue with the left medial umbilical ligament. The patient's postoperative course was uneventful, and follow‑up imaging showed no evidence of recurrence. Τhe present case report is the first non‑syndromic case with left umbilical medial ligament‑originated","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":" 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138620263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
. Breast carcinoma arising from a fibroadenoma is an uncommon entity and is frequently detected incidentally during pathological examination or excisional biopsy of a benign breast tumor. Due to only sporadic cases being reported, evidence‑based guidelines are not well‑established to date. The present report describes 16 patients diagnosed with breast carcinoma arising within a fibroadenoma in the Third Hospital of Nanchang (Nanchang, China) between January 2019 and December 2021 and discusses the clinicopatho‑ logical characteristics, imaging findings and treatment. The age of patients at diagnosis ranged between 19 and 58 years and a well‑defined asymptomatic mass was the most common clinical presentation. Carcinoma occurring in fibroadenoma generally mimics a benign tumor and potential carcinoma‑ tous changes may not be detected. Pathologically, carcinoma in situ was the predominant subtype in the present study. Additionally, ductal carcinoma in situ was more common compared with lobular carcinoma in situ in the present case series. Regarding the molecular phenotypes, the majority of cases were categorized as luminal subtype, although other subtypes such as triple‑negative and HER2 positive breast cancer were also identified. In the present study, seven patients were treated with breast‑conserving surgery and nine patients were treated with mastectomy. Sentinel lymph node biopsy was performed in all patients and none exhibited axillary node metastasis. Additionally, six patients underwent radiotherapy and two received chemotherapy. During the follow‑up, all patients were alive and no evidence of disease relapse was observed. In summary, clinicians should be aware of the possibility of carcinoma within a fibroadenoma, which could alter the therapeutical course. Adequate biopsy or excision should be performed in patients with indicators of malignant transformation in a presumed benign breast tumor.
{"title":"Breast carcinoma arising in a fibroadenoma: A case series of 16 patients and review of the literature","authors":"Liang Xu, Shuya Luo, Qixin Mao, Yufeng Gao, Lihua Luo, Wei Qu, Yali Cao","doi":"10.3892/ol.2023.14172","DOIUrl":"https://doi.org/10.3892/ol.2023.14172","url":null,"abstract":". Breast carcinoma arising from a fibroadenoma is an uncommon entity and is frequently detected incidentally during pathological examination or excisional biopsy of a benign breast tumor. Due to only sporadic cases being reported, evidence‑based guidelines are not well‑established to date. The present report describes 16 patients diagnosed with breast carcinoma arising within a fibroadenoma in the Third Hospital of Nanchang (Nanchang, China) between January 2019 and December 2021 and discusses the clinicopatho‑ logical characteristics, imaging findings and treatment. The age of patients at diagnosis ranged between 19 and 58 years and a well‑defined asymptomatic mass was the most common clinical presentation. Carcinoma occurring in fibroadenoma generally mimics a benign tumor and potential carcinoma‑ tous changes may not be detected. Pathologically, carcinoma in situ was the predominant subtype in the present study. Additionally, ductal carcinoma in situ was more common compared with lobular carcinoma in situ in the present case series. Regarding the molecular phenotypes, the majority of cases were categorized as luminal subtype, although other subtypes such as triple‑negative and HER2 positive breast cancer were also identified. In the present study, seven patients were treated with breast‑conserving surgery and nine patients were treated with mastectomy. Sentinel lymph node biopsy was performed in all patients and none exhibited axillary node metastasis. Additionally, six patients underwent radiotherapy and two received chemotherapy. During the follow‑up, all patients were alive and no evidence of disease relapse was observed. In summary, clinicians should be aware of the possibility of carcinoma within a fibroadenoma, which could alter the therapeutical course. Adequate biopsy or excision should be performed in patients with indicators of malignant transformation in a presumed benign breast tumor.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"115 14","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138609321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anamorelin, a ghrelin receptor agonist, is approved in Japan for the treatment of cachexia in patients with lung and gastrointestinal cancer. However, there is limited research on the usefulness of anamorelin in clinical settings, therefore, the present study evaluated its efficacy using patient characteristics. A total of 40 patients with non-small cell lung cancer and cachexia who were prescribed anamorelin in the Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine (Aomori, Japan) between July 2021 and November 2022, were retrospectively assessed. Anamorelin was prescribed at a dose of 100 mg once daily to patients who had lost >5% of their body weight within 6 months. All patients were weighed before treatment and those who continued anamorelin treatment for 12 weeks were also weighed at 12 weeks. A logistic regression analysis was used to analyze the association between background characteristics and early discontinuation of treatment with anamorelin (within 4 weeks). The median age was 67 years (range, 36-88), and 65% of the patients were male. There were 24 patients (60.0%) with an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score 1, 11 patients (27.5%) with an ECOG-PS score 2 and five patients (12.5%) with an ECOG-PS score 3. The early discontinuation group included 11 patients (27.5%). An ECOG-PS score ≥2 (odds ratio, 7.85; 95% confidence interval, 1.43-43.21; P=0.018) was associated with early discontinuation. A total of 18/40 patients (45.0%) were able to continue anamorelin treatment for 12 weeks, and the mean change in body weight was +2.31 kg, which was a significant change from the weight recorded at baseline (P=0.027). The mean changes in lean body mass and soft lean mass between baseline and 12 weeks were +1.97 kg (P=0.14) and +1.26 kg (P=0.15), respectively. The results from the present study indicate that anamorelin is unlikely to be useful for patients with a poor general condition (ECOG-PS score ≥2).
Anamorelin是一种胃饥饿素受体激动剂，在日本被批准用于治疗肺癌和胃肠道癌症患者的恶病质。然而，关于阿纳莫瑞林在临床环境中的有效性的研究有限，因此，本研究使用患者特征来评估其疗效。回顾性评估了2021年7月至2022年11月期间在hiroaki大学医学研究生院(Aomori, Japan)呼吸医学系接受anamorelin治疗的40例非小细胞肺癌和恶病质患者。阿纳莫瑞林的剂量为100毫克，每日一次，用于6个月内体重减轻>5%的患者。所有患者在治疗前称重，持续阿纳莫瑞林治疗12周的患者也在12周时称重。采用logistic回归分析分析背景特征与早期停用阿纳莫瑞林(4周内)之间的关系。中位年龄为67岁(36-88岁)，65%的患者为男性。ECOG-PS评分为1分的患者24例(60.0%)，ECOG-PS评分为2分的患者11例(27.5%)，ECOG-PS评分为3分的患者5例(12.5%)。早期停药组11例(27.5%)。ECOG-PS评分≥2(优势比，7.85;95%置信区间为1.43 ~ 43.21;P=0.018)与早期停药相关。共有18/40例患者(45.0%)能够继续阿纳莫瑞林治疗12周，体重平均变化为+2.31 kg，与基线时记录的体重相比有显著变化(P=0.027)。基线至12周期间，瘦体重和软瘦体重的平均变化分别为+1.97 kg (P=0.14)和+1.26 kg (P=0.15)。本研究的结果表明，anamorelin不太可能对一般情况较差(ECOG-PS评分≥2)的患者有用。
{"title":"Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.","authors":"Yoshiko Ishioka, Hisashi Tanaka, Tomonori Makiguchi, Syunsuke Fujishima, Yasuhito Nunomura, Hiroaki Sakamoto, Toshihiro Shiratori, Kageaki Taima, Sadatomo Tasaka","doi":"10.3892/ol.2023.14154","DOIUrl":"10.3892/ol.2023.14154","url":null,"abstract":"<p><p>Anamorelin, a ghrelin receptor agonist, is approved in Japan for the treatment of cachexia in patients with lung and gastrointestinal cancer. However, there is limited research on the usefulness of anamorelin in clinical settings, therefore, the present study evaluated its efficacy using patient characteristics. A total of 40 patients with non-small cell lung cancer and cachexia who were prescribed anamorelin in the Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine (Aomori, Japan) between July 2021 and November 2022, were retrospectively assessed. Anamorelin was prescribed at a dose of 100 mg once daily to patients who had lost >5% of their body weight within 6 months. All patients were weighed before treatment and those who continued anamorelin treatment for 12 weeks were also weighed at 12 weeks. A logistic regression analysis was used to analyze the association between background characteristics and early discontinuation of treatment with anamorelin (within 4 weeks). The median age was 67 years (range, 36-88), and 65% of the patients were male. There were 24 patients (60.0%) with an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score 1, 11 patients (27.5%) with an ECOG-PS score 2 and five patients (12.5%) with an ECOG-PS score 3. The early discontinuation group included 11 patients (27.5%). An ECOG-PS score ≥2 (odds ratio, 7.85; 95% confidence interval, 1.43-43.21; P=0.018) was associated with early discontinuation. A total of 18/40 patients (45.0%) were able to continue anamorelin treatment for 12 weeks, and the mean change in body weight was +2.31 kg, which was a significant change from the weight recorded at baseline (P=0.027). The mean changes in lean body mass and soft lean mass between baseline and 12 weeks were +1.97 kg (P=0.14) and +1.26 kg (P=0.15), respectively. The results from the present study indicate that anamorelin is unlikely to be useful for patients with a poor general condition (ECOG-PS score ≥2).</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"27 1","pages":"22"},"PeriodicalIF":2.9,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：